Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This study assesses the effects of voriconazole, 200 mg, administered twice daily (BID), on
the steady-state pharmacokinetics of atazanavir administered as atazanavir/ritonavir, 300/100
mg once daily (QD), in healthy participants with functional CYP2C19 alleles. The study also
reviews the effects of atazanavir/ritonavir, 300/100 mg QD, on the pharmacokinetics of
voriconazole, 200 mg, BID in healthy participants with functional CYP2C19 alleles.